InVivo Therapeutics Announces First Canadian Site for Cervical … – Yahoo Finance

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

InVivo Therapeutics Holdings Corp. (NVIV)today announced that it has received approval from the Toronto Western Hospitals Research Ethics Board to enroll patients as part of its cervical spinal cord injury study. Toronto Western Hospital is the first study site for the companys cervical spinal cord injury study and Michael Fehlings, M.D., Ph.D., has been named Principal Investigator at the site. Dr. Fehlings is currently Director of the Spinal Program, part of Toronto Western Hospitals Krembil Neuroscience Centre at the University Health Network, Professor in the Department of Surgery, full member of the Institute of Medical Sciences School of Graduate Studies, a Scholar in the McLaughlin Centre of Molecular Medicine, a Scientist in the McEwen Centre for Regenerative Medicine, a Senior Scientist at the Krembil Research Institute, Director of the University of Toronto Neuroscience Program, Co-Director of the University of Toronto Spine Program, and Krembil Chair in Neural Repair and Regeneration. Dr. Fehlings has published over 725 peer-reviewed articles principally in the area of spinal cord injury and complex spinal surgery. He is also currently the Principal Investigator at the site for InVivos INSPIRE study, which is studying the Neuro-Spinal Scaffold in acute, complete (AIS A) thoracic patients.

Dr. Fehlings said, Our centre remains enthusiastic about addressing the unmet need in cervical spinal cord injuries and being part of InVivos pioneering efforts in this exciting and promising field.

We are thrilled to launch our cervical study in Canada with one of the most prominent leaders in spinal cord injury research, Mark Perrin, InVivos CEO and Chairman, said. We admire Dr. Fehlings and Toronto Western Hospitals dedication to helping us evaluate our technology through both the cervical study and the INSPIRE study. We look forward to continuing to work with Dr. Fehlings and Toronto Western Hospital.

About the Neuro-Spinal Scaffold Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in the INSPIRE pivotal probable benefit study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Childrens Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the companys investigational Neuro-Spinal Scaffold received the 2015 Beckers Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit http://www.invivotherapeutics.com.

Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "believe," "anticipate," "intend," "estimate," "will," "may," "should," "expect," designed to, potentially, and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the companys ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the companys ability to commercialize its products; the companys ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the companys products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the companys business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the companys Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the SEC, including the companys Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005272/en/

Link:
InVivo Therapeutics Announces First Canadian Site for Cervical ... - Yahoo Finance